Dr. Reem Md Karmali, MD

Dr. Karmali practices at Northwestern Medical Group in Chicago, Illinois.

Dr. Karmali's NPI, 1083860282, was assigned on August 7, 2008. Dr. Karmali holds Illinois license 036.123267.

Dr. Karmali's primary practice is Northwestern Medical Group, at 675 N St Clair St, Chicago, IL 60611 in Cook County. The practice phone is (312) 695-0646.

Dr. Karmali's primary practice is Northwestern Medical Group in Chicago, Illinois. Dr. Karmali is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Karmali to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karmali practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Karmali's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Karmali is licensed in Illinois.

CMS data shows 10,765 Medicare services from Dr. Karmali across 26 procedure codes in 2024, for 389 Medicare patients. Medicare paid $378,761 for them.

CMS counts 389 Medicare patients who saw Dr. Karmali in 2024. The largest group is 65 to 74, with 185 patients. 69% of them have high cholesterol, and 64% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karmali's median patient age at 70, with 51% women.

In 2024, Dr. Karmali wrote 831 Medicare Part D claims for 99 patients. 83% of them were for generic drugs. CMS names the drug for 564 of them, across 19 drugs with 11 or more claims each, at $788,129 in total drug cost. In 2023, CMS named 335 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Karmali for performance year 2024, reported through an alternative payment model (APM). Dr. Karmali accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Karmali as offering telehealth.

Dmand AI links 113 papers to Dr. Karmali, published from 2011 to 2025. 2021 was the busiest year, with 11. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Immunotherapy, Adoptive. Dr. Karmali has published most often in Blood Adv. Dr. Karmali's most frequent co-authors are Leo I. Gordon, MD, Jane N. Winter, MD and Pallawi Torka, MD.

Dmand AI links Dr. Karmali to 10 clinical trials, 5 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin. Northwestern University sponsors the most, 4. Open Payments lists research payments to Dr. Karmali that name 1 trial.

CMS Open Payments shows 303 general payments to Dr. Karmali from 19 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. AstraZeneca Pharmaceuticals LP paid the most, $67,609. It also lists 2 research payments totaling $125 from 2019 to 2025, naming 1 clinical trial.